In its proprietary protease inhibitor program against hepatitis C infection, Achillion nominated ACH-2684, a compound that demonstrates excellent potency in the low pico-molar range, as well as good pharmacokinetic and safety profiles in preclinical studies.
The potency and virology profile of ACH-2684 demonstrates that it very effectively suppresses a broad range of natural variants of the hepatitis C virus, and may be effective in prevention and treatment of emerging resistant variants. This compound also retains potent activity against all genotypes.
Program Overview
The very high potency of ACH-2684 was achieved by optimizing its interactions against NS3 protease. Achillion has demonstrated in vitro that ACH-2684 can be used in combination with other HCV inhibitors, and that it is synergistic with NS5B nucleoside polymerase inhibitors. more
Data Overview
ACH-2684 demonstrates exceptional potency, with inhibition of HCV variants at pico-molar potency range. more
